KATIE CREIGHTON: Open Payments
NPI 1467717298 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,237 in 94 payments from 28 companies in 2025. Trend: 2023 $2,069 · 2024 $2,264 · 2025 $2,237
Food & beverage: $2,177Education: $60
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $434 |
| ABBVIE INC. | 18 | $262 |
| PFIZER INC. | 9 | $222 |
| Amgen Inc. | 11 | $207 |
| Teva Pharmaceuticals USA, Inc. | 6 | $135 |
| Sumitomo Pharma America, Inc. | 5 | $126 |
| Novo Nordisk Inc | 5 | $84 |
| Astellas Pharma US Inc | 2 | $77 |
| Corcept Therapeutics | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
Products named: BREZTRI, AUSTEDO XR, AIRSUPRA, GEMTESA, KRYSTEXXA, REXULTI, UBRELVY, VRAYLAR.
Industry payments across MD — which companies pay providers there.
